In the intention-to-treat population with previously untreated advanced renal cell carcinoma, at a median follow-up of 67.6 months (60.2 months minimum), CheckMate 9ER data for Cabozantinib + nivolumab demonstrated:²

Almost double the median progression-free survival vs sunitinib²

Sustained long-term overall survival at 67.6 months versus sunitinib²

Established patient safety and tolerability profile²

An established safety profile with no new safety signals compared with the previous cut-off was seen in the 67.6-month follow-up²
Discontinuation rates due to TRAEs with Cabozantinib + nivolumab were 6% simultaneously and 1% sequentially, 11% for Cabozantinib alone, 10% for nivolumab alone and 11% with sunitinib.²

One tablet, once a day with adjustable dosing¹

Cabozantinib is taken as one tablet, once daily with a recommended starting dose of 40 mg when administered in combination with nivolumab.¹ Management of suspected adverse drug reactions may require temporary treatment interruption and/or dose reduction.¹

Dosing can be reduced to 20 mg once daily, then 20 mg every other day to manage TRAEs, if required.¹